ViiV Healthcare and Janssen Pharmaceutical’s Cabenuva treatment for people living with human immunodeficiency virus (HIV-1) received a label update as adult patients now have the option to start the injectable regimen without the need for an oral lead-in period first.

Civica Rx announced the organization’s intentions to manufacture and distribute insulins that will be available to individuals with diabetes at lower prices than those presently on the market.

The U.S health regulator declined to approve Gilead Sciences’ injectable drug for the treatment of HIV-1 infection over concerns related to the vials meant for the drug, the company said on March 1.

The U.S. Food and Drug Administration approved the use of Purdue Pharma’s candidate injectable treatment for partially or completely reversing opioid drug effects.

Cosette Pharmaceuticals Inc., a New Jersey-based pharmaceutical company, announced the launch of Prochlorperazine Edisylate injection, 10 mg/2ml (5mg/ml).

The latest results from Genentech’s proposed eye disease treatments are demonstrating strong potential to help reduce treatment frequencies and deliver improved outcomes.  

Britain’s GlaxoSmithKline will receive $1.25 billion from Gilead Sciences as part of a settlement between GSK’s HIV medicines unit and the U.S.-based drugmaker, ending a long-drawn patent dispute.

ViiV Healthcare’s HIV treatment Cabenuva was approved by the U.S. Food and Drug Administration for use every two months, meaning patients only have to receive an injectable dose six times per year.

GSK and Vir Biotechnology said on January 13 they are seeking an expansion to the U.S. approval of their antibody-based COVID-19 treatment to include an option for the therapy to be given as a shot in the arm.

Teva Pharmaceutical announced positive results from the company’s Phase III trial on a subcutaneous, long-acting injectable risperidone formulation in the treatment of schizophrenia.